Added to YB: 2026-09-11
Pitch date: 2026-09-09
VYGR [neutral]
Voyager Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Market Cap
$200.3M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.81
P/E
-1.79
EV/Sales
2.44
Sector
Biotechnology
Category
growth
Wells Fargo Healthcare Conference Biotech day 1 Batch 3 - Voyager Therapeutics — VYGR 78/74
VYGR (quick overview): Voyager is a CNS delivery-platform company whose major value driver is proving its capsid can safely and broadly deliver genetic medicines throughout the human CNS. The immediate catalyst is VY7523’s Q4 2026 multiple-ascending-dose readout; Voyager says it may terminate the program if Tau-PET performance falls short of bepranemab. The larger opportunity, VY1706, produced approximately 60–70% brain Tau knockdown in non-human primates, according to Voyager, but human BBB crossing, safety and CSF Tau reduction remain key uncertainties.
Read full article (1 min)